406923-91-9

Basic information

• Product Name: 7-FLUORO-1,2,3,4-TETRAHYDRO-ISOQUINOLINE
• Synonyms: Isoquinoline, 7-fluoro-1,2,3,4-tetrahydro- (9CI);Isoquinoline, 7-fluoro-1,2,3,4-tetrahydro-
• CAS NO: 406923-91-9
• Molecular Formula: C₉H₁₀FN
• Molecular Weight: 151.18
• EINECS: 604-604-1
• Product Categories: HALIDE
• Mol File: 406923-91-9.mol

Chemical Properties

• Boiling Point: 227.6 °C at 760 mmHg
• Flash Point: 91.4 °C
• Appearance: /
• Density: 1.107 g/cm³
• Storage Temp.: 2-8°C(protect from light)
• PKA: 9.29±0.20(Predicted)
• CAS DataBase Reference: 7-FLUORO-1,2,3,4-TETRAHYDRO-ISOQUINOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 7-FLUORO-1,2,3,4-TETRAHYDRO-ISOQUINOLINE(406923-91-9)
• EPA Substance Registry System: 7-FLUORO-1,2,3,4-TETRAHYDRO-ISOQUINOLINE(406923-91-9)

Safety Data

• Hazardous Substances Data: 406923-91-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
7-Fluoro-1,2,3,4-tetrahydro-isoquinoline is used as a building block for the synthesis of pharmaceuticals due to its potential biological activities and pharmacological properties. It is particularly valuable in the development of new drugs with analgesic and antipsychotic effects.
Used in Agrochemical Industry:
In the agrochemical industry, 7-fluoro-1,2,3,4-tetrahydro-isoquinoline is utilized as a key component in the synthesis of agrochemicals, contributing to the development of effective and innovative products for agricultural applications.
Used in Fine Chemicals Industry:
7-Fluoro-1,2,3,4-tetrahydro-isoquinoline is employed as a precursor in the synthesis of various heterocyclic compounds in the fine chemicals industry. Its unique structure and properties make it a promising candidate for the creation of novel compounds with potential applications in various fields.
Used in Drug Discovery and Development:
7-Fluoro-1,2,3,4-tetrahydro-isoquinoline is used as a precursor in drug discovery and development, where it aids in the synthesis of new compounds with potential therapeutic applications. Its investigation for biological activities and pharmacological properties highlights its importance in the advancement of medicinal chemistry.

Upstream product

• 885273-83-6 7-fluoro-3,4-dihydro-2H-isoquinolin-1-one 
• 912846-64-1 2,2,2-trifluoro-1-(7-fluoro-1,2,3,4-tetrahydroisoquinolin-2-yl)ethan-1-one 
• 912846-63-0 2,2,2-trifluoro-N-[2-(4-fluorophenyl)ethyl]acetamide 
• 1583-88-6 4-fluoro-2-phenethylamine 

Downstream Products

• 1236265-31-8 N-ethyl-4-((4-(7-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-1,3,5-triazin-2-ylamino)methyl)-N-m-tolylbenzamide 
• 1028330-60-0 C₂₉H₃₃FN₂O 

Relevant articles and documents

Photocatalytic deaminative benzylation and alkylation of tetrahydroisoquinolines with N-alkylpyrydinium salts

A ruthenium-catalyzed photoredox coupling of substituted N-aryltetrahydroisoquinolines (THIQs) and different bench-stable pyridinium salts was successfully developed to give fast access to 1-benzyl-THIQs. Furthermore, secondary alkyl and allyl groups were also successfully introduced via the same method. Additionally, the typically applied N-phenyl group in the THIQ substrate could be replaced by the cleavable p-methoxyphenyl (PMP) group and successful N-deprotection was demonstrated.

Intramolecular Reductive Cyclization of o-Nitroarenes via Biradical Recombination

A visible-light-induced/thiourea-mediated intramolecular cyclization of o-nitroarenes under mild conditions is realized for the first time, which provides an efficient and environmentally friendly way to access pharmaceutical relevant quinazolinone derivatives. The reaction can be easily extended to gram level by using a continuous-flow setup with high efficiency. Mechanistic investigation including control experiments, transient fluorescence, UV-vis spectra, and DFT calculations suggests that the formation of active biradical intermediates via intramolecular single electron transfer (SET) is key stage in the catalytic cycle.

Catalyst-free cyclization of anthranils and cyclic amines: One-step synthesis of rutaecarpine

An efficient synthesis of a variety of quinazolinone derivatives via a direct cyclization reaction between commercially available anthranils and cyclic amines is described. The developed transformation proceeds with the merits of high step- and atom-efficiency, a broad substrate scope, and good to excellent yields, without additional catalysts, and offers a practical way for the preparation of rutaecarpine and its derivatives with structural diversity.

Light-Driven Intramolecular C?N Cross-Coupling via a Long-Lived Photoactive Photoisomer Complex

Reported herein is a visible-light-driven intramolecular C?N cross-coupling reaction under mild reaction conditions (metal- and photocatalyst-free, at room temperature) via a long-lived photoactive photoisomer complex. This strategy was used to rapidly prepare the N-substituted polycyclic quinazolinone derivatives with a broad substrate scope (>50 examples) and further exploited to synthesize the natural products tryptanthrin, rutaecarpine, and their analogues. The success of gram-scale synthesis and solar-driven transformation, as well as promising tumor-suppressing biological activity, proves the potential of this strategy for practical applications. Mechanistic investigations, including control experiments, DFT calculations, UV-vis spectroscopy, EPR, and X-ray single-crystal structure of the key intermediate, provides insight into the mechanism.

TRIAZOLOPHTHALAZINE COMPOUNDS, USE AS ANTI-HUMAN IMMUNODEFICIENCY VIRUS INHIBITORS OF HIV VIF-DEPENDENT DEGRADATION OF APOBEC3

The present disclosure is concerned with triazolophthalazine compounds that are capable of inhibiting infection by the Human Immunodeficiency Virus (HIV) by inhibiting HIV Vif-dependent degradation of the APOBEC3 innate immune system. The present disclosu

Heterocyclic compound with Wnt signal path inhibitory activity and application thereof

The invention provides a heterocyclic compound with Wnt signal path inhibitory activity. The heterocyclic compound and chemically acceptable salt, isotope, isomer and a crystal structure thereof are provided with a structure shown as the general formula I (see the formula in the description). The invention further provides application of the heterocyclic compound with the Wnt signal path inhibitory activity. The heterocyclic compound with the Wnt signal path inhibitory activity serves as effective antagonist of a Wnt signal path, and can be used for treating or preventing diseases caused by abnormity of the Wnt signal path.